Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Veritas In Silico Inc. ( (JP:130A) ).
Veritas In Silico Inc. and The Jikei University School of Medicine have initiated a joint research project to develop new therapeutics and drug delivery systems that enhance treatment efficacy while minimizing side effects. This collaboration aims to improve patient quality of life by reducing medication dosages and ensuring drugs effectively reach target organs, with Veritas In Silico designing drug candidates and The Jikei University conducting in vivo evaluations.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapeutics and drug delivery methods. The company aims to enhance therapeutic efficacy and reduce side effects through efficient drug delivery to target organs.
Average Trading Volume: 275,078
Technical Sentiment Signal: Hold
Current Market Cap: Yen4.66B
See more data about 130A stock on TipRanks’ Stock Analysis page.